Gilead Sciences, Inc. (NASDAQ:GILD) Holdings Cut by Collective Family Office LLC

Collective Family Office LLC lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) by 41.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,407 shares of the biopharmaceutical company’s stock after selling 1,696 shares during the quarter. Collective Family Office LLC’s holdings in Gilead Sciences were worth $207,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. JFS Wealth Advisors LLC increased its stake in shares of Gilead Sciences by 68.1% in the third quarter. JFS Wealth Advisors LLC now owns 400 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 162 shares during the period. Pacifica Partners Inc. increased its stake in shares of Gilead Sciences by 179.7% in the third quarter. Pacifica Partners Inc. now owns 414 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 266 shares during the period. Horan Securities Inc. increased its stake in shares of Gilead Sciences by 217.9% in the third quarter. Horan Securities Inc. now owns 461 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 316 shares during the period. Capital Advisors Ltd. LLC increased its stake in shares of Gilead Sciences by 29.4% in the third quarter. Capital Advisors Ltd. LLC now owns 607 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 138 shares during the period. Finally, Wagner Wealth Management LLC acquired a new stake in shares of Gilead Sciences in the second quarter valued at approximately $42,000. Institutional investors and hedge funds own 78.72% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the topic of several analyst reports. Cowen raised their price target on shares of Gilead Sciences from $90.00 to $95.00 in a research note on Friday, February 10th. SVB Leerink raised their price objective on shares of Gilead Sciences from $81.00 to $91.00 and gave the company a “market perform” rating in a research note on Friday, February 3rd. Royal Bank of Canada lowered their price objective on shares of Gilead Sciences from $87.00 to $86.00 and set a “sector perform” rating on the stock in a research note on Monday, March 6th. Oppenheimer raised their price objective on shares of Gilead Sciences from $95.00 to $105.00 in a research note on Thursday, December 1st. Finally, Bank of America reiterated a “neutral” rating and set a $85.00 price objective on shares of Gilead Sciences in a research note on Tuesday, December 13th. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $89.40.

Insider Buying and Selling

In other Gilead Sciences news, insider Merdad Parsey sold 6,126 shares of Gilead Sciences stock in a transaction on Monday, March 13th. The shares were sold at an average price of $78.99, for a total transaction of $483,892.74. Following the completion of the sale, the insider now owns 70,130 shares of the company’s stock, valued at approximately $5,539,568.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Trading Down 3.2 %

Gilead Sciences stock opened at $77.31 on Friday. The company has a 50 day moving average price of $83.20 and a 200 day moving average price of $78.51. Gilead Sciences, Inc. has a 52 week low of $57.17 and a 52 week high of $89.74. The company has a debt-to-equity ratio of 1.14, a quick ratio of 1.15 and a current ratio of 1.29. The firm has a market capitalization of $96.41 billion, a price-to-earnings ratio of 21.18, a P/E/G ratio of 0.95 and a beta of 0.38.

Gilead Sciences (NASDAQ:GILD – Get Rating) last posted its quarterly earnings data on Thursday, February 2nd. The biopharmaceutical company reported $1.67 EPS for the quarter, topping analysts’ consensus estimates of $1.50 by $0.17. Gilead Sciences had a net margin of 16.83% and a return on equity of 44.46%. The firm had revenue of $7.39 billion during the quarter, compared to analyst estimates of $6.63 billion. During the same quarter last year, the business posted $0.69 EPS. The company’s revenue was up 2.0% on a year-over-year basis. Research analysts forecast that Gilead Sciences, Inc. will post 6.86 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 30th. Investors of record on Wednesday, March 15th will be paid a $0.75 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.73. The ex-dividend date of this dividend is Tuesday, March 14th. This represents a $3.00 dividend on an annualized basis and a yield of 3.88%. Gilead Sciences’s dividend payout ratio (DPR) is currently 82.19%.

About Gilead Sciences

(Get Rating)

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.